[1]田源,张良安.放射免疫治疗中的α核素微剂量研究[J].国际放射医学核医学杂志,2006,30(1):39-41.
　TIAN Yuan,ZHANG Liang-an.A review of microdosimetric study in alpha particle radioimmunotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):39-41.
点击复制

放射免疫治疗中的α核素微剂量研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
30
期数:
2006年第1期
页码:
39-41
栏目:
医用内照射剂量
出版日期:
1900-01-01

文章信息/Info

Title:
A review of microdosimetric study in alpha particle radioimmunotherapy
作者:
田源;  张良安
300192 天津, 中国医学科学院中国协和医科大学放射医学研究所保健物理研究室
Author(s):
TIAN Yuan;  ZHANG Liang-an
Department of Health Physics, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China
关键词:
α粒子; 放射免疫治疗; 微剂量
Keywords:
α-Particle; Radioimmunotherapy; Microdosimetry
分类号:
R144.1
摘要:
微剂量研究在临床α核素放免治疗的计划设计和疗效评价中起重要作用。设计一整套既能准确描述α粒子在细胞、亚细胞水平上剂量的不均匀分布,又适于临床使用的微剂量估算模型,一直是该领域的重要研究内容。本文介绍了α核素微剂量计算的几种常用方法以及最新发现的显著影响其结果精确度的因素。
Abstract:
Microdosimetry plays an important role in the clinical application of alpha-particle radioimmunotherapy. There is increasing interest to develop a set of microdosimetric model, which can exactly describe the nonuniformly distribution of dose at cellular or sub-cellular level as well as can be conveniently used in clinic. In this paper, introduce some common methods of microdosimetry and some important affective factors reported in current researches on alpha-particle radioimmunotherapy.

参考文献/References:

1 Goddu SM,Howell RW,Bouchet LG,et al.MIRD cellular s values:self-Absorbed dose per unit cumulated activity for selected radionuclides and monoenergetic electron and alpha particle emitters incorporated into,850 samuel morse drive,reston,VA20190-5136:Society of Nuclear Medicine,1997
2 Wilson WE,Nikjoo H.A monte carlo code for positive ion track simulation.Radiat Environ Biophys,1999,38(2):97-104.
3 Aubineau-Laniece I,Pihet P,Winkler R,et al.Monte carlo code for microdosimetry of inhaled alpha emitters.Radiat Prot Dosimetry,2002,99(1-4):463-468.
4 Stewart RD,Wilson WE,Mcdonald JC,et al.Microdosimetric properities of ionizing electrons in water:a test of the PENELOPE code system.Phys Med Biol,2002,47(1):79-88.
5 Tung CJ,Liu CS,Wang JP,et al.Calculation of cellular microdosimetry parameters for alpha particles and electrons.Appl Radiat Isot,2004,61(5):739-743.
6 Roeske JC,Stinchcomb TG.Tumor control probability model for alphaparticle-emitting radionuclides.Radiat Res,2000,153(1):16-22.
7 Kvinnsland Y,Stokke T,Aurlien E.Radioimmunotherapy with alpha-particle emitters:microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei.Radiat Res,2001,155(2):288-296.
8 Palm S,Humm JL,Rundqvist R,et al.Microdosimetry of astatine-211 single-cell irradiation:role of daughter polonium-211 diffusion.Med Phys,2004,31(2):218-225.
9 ICRP.Limits for Intakes of Radionuclides by workers.International Com-mission on Radiological Protection,Pubilication 30.Oxford,UK:Pergamon,1979.
10 Bolch WE.α-particle emitters in radioimmunotherapy:new and welcome challenges to medical internal dosimetry.J Nucl Med,2001,42(8):1222-1224.
11 Ünak T.Some microdosimetrc data on Astatine-211.Appl Radiat Isot,2003,58(1):115-117.

相似文献/References:

[1]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
　Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[2]王丽琴,屈喜梅,焦玲,等.水中总α、β放射性测量概述[J].国际放射医学核医学杂志,2012,36(3):164.[doi:10.3760/cma.j.issn.1673-4114.2012.03.011]
　WANG Li-qin,Qu Xi-mei,JIAO Ling,et al.Measurement of gross α and gross β radioactivity in water[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):164.[doi:10.3760/cma.j.issn.1673-4114.2012.03.011]
[3]陈立波,朱瑞森.Bexxar治疗非霍奇金淋巴瘤的研究现状[J].国际放射医学核医学杂志,2005,29(2):67.
　CHEN Li-bo,ZHU Rui-sen.Current status of Bexxar for treatment of non-Hodgkin’s lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(1):67.
[4]高云朝.恶性胶质瘤的放射免疫治疗[J].国际放射医学核医学杂志,2004,28(4):149.
　GAO Yun-chao.Radioimmunotherapy for malignant glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(1):149.
[5]仲恒高,童建.α粒子辐射与基因组不稳定性[J].国际放射医学核医学杂志,2004,28(6):267.
　ZHONG Heng-gao,TONG Jian.Alpha-particles radiation and genomic instability[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(1):267.
[6]张弘.用于放免治疗的核素研究进展[J].国际放射医学核医学杂志,2003,27(4):148.
　ZHANG Hong.Advances in radionuclide for radioimmunotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(1):148.
[7]李敏杰.胰腺癌的放射免疫治疗进展[J].国际放射医学核医学杂志,2003,27(4):154.
　LI Min-jie.Radioimmunotherapy of pancreatic cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(1):154.
[8]袁志斌.ZevalinTM:一种放射免疫治疗新药[J].国际放射医学核医学杂志,2002,26(5):225.
　YUAN Zhi-bin.ZevalinTM: A new radioimmunotherapy agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(1):225.
[9]任均田,林学颜.放射免疫显像与治疗的应用进展[J].国际放射医学核医学杂志,1995,19(2):57.
[10]唐刚华,王世真.生物素-亲合素系统在核医学中的应用[J].国际放射医学核医学杂志,1997,21(4):145.

备注/Memo

备注/Memo:
收稿日期:2005-03-28。
更新日期/Last Update: 1900-01-01